The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Nonalcoholic fatty liver disease, circulating ketone bodies and all-cause mortality in a general population-based cohort
Eur J Clin Invest. 2021 Jun 13;e13627. doi: 10.1111/eci.13627. Online ahead of print.
Adrian Post1, Erwin Garcia2, Eline H van den Berg3, Jose L Flores-Guerrero1, Eke G Gruppen1, Dion Groothof1, Berend Daan Westenbrink4, Margery A Connelly2, Stephan J L Bakker1, Robin P F Dullaart1
Author information
1Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
2Laboratory Corporation of America Holdings (Labcorp), Morrisville, NC, USA.
3Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
4Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent, paralleling the obesity epidemic. Ketone bodies are produced in the liver, but it is currently uncertain whether circulating ketone bodies are increased in the context of NAFLD. We investigated the association between NAFLD and circulating ketone bodies and determined the extent to which NAFLD and circulating ketone bodies are associated with all-cause mortality.
Methods: Plasma ketone bodies were measured by nuclear magnetic resonance spectroscopy in participants of the general population-based PREVEND study. A fatty liver index (FLI) ≥60 was regarded as a proxy of NAFLD. Associations of an elevated FLI and ketone bodies with all-cause mortality were investigated using Cox regression analyses.
Results: The study included 6,297 participants aged 54 ± 12 years, of whom 1,970 (31%) had elevated FLI. Participants with elevated FLI had higher total ketone bodies (194 [153-259] vs 170 [133-243] µmol/L; P < .001) than participants without elevated FLI. During 7.9 [7.8-8.9] years of follow-up, 387 (6%) participants died. An elevated FLI was independently associated with an increased risk of mortality (HR: 1.34 [1.06-1.70]; P = .02). Higher total ketone bodies were also associated with an increased mortality risk (HR per doubling: 1.29 [1.12-1.49]; P < .001). Mediation analysis suggested that the association of elevated FLI with all-cause mortality was in part mediated by ketone bodies (proportion mediated: 10%, P < .001).
Conclusion: Circulating ketone bodies were increased in participants with suspected NAFLD. Both suspected NAFLD and higher circulating ketone bodies are associated with an increased risk of all-cause mortality.